🎉 M&A multiples are live!
Check it out!

Grape King Bio Valuation Multiples

Discover revenue and EBITDA valuation multiples for Grape King Bio and similar public comparables like Benevolent AI, Julphar, and Vivoryon Therapeutics.

Grape King Bio Overview

About Grape King Bio

Grape King Bio Ltd is a specialty and generic drug manufacturing company engaged in producing and selling pharmaceutical preparations, patent medicine, liquid tonic, drink, and healthy food. The company has three segments: MLM (Multi-Level Marketing) is a direct seller of Pro-partner Inc, including the company’s development and manufacturing products for Pro-partner Inc, Distributors segment includes the company’s self-owned brand products, and ODM/OEM (Original Design Manufacturer/Original Equipment Manufacturer) includes ODM/OEM in Taiwan and Shanghai. The group operates in three principal geographical areas - Taiwan, China, and Others, and it derives a majority of its revenue from Taiwan.


Founded

1969

HQ

Taiwan
Employees

565

Financials

LTM Revenue $343M

LTM EBITDA n/a

EV

$464M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Grape King Bio Financials

Grape King Bio has a last 12-month revenue of $343M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Grape King Bio achieved revenue of $337M and an EBITDA of $96.3M.

Grape King Bio expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Grape King Bio valuation multiples based on analyst estimates

Grape King Bio P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $321M $337M XXX XXX XXX
Gross Profit $256M $258M XXX XXX XXX
Gross Margin 80% 76% XXX XXX XXX
EBITDA $94.3M $96.3M XXX XXX XXX
EBITDA Margin 29% 29% XXX XXX XXX
Net Profit $44.0M $43.9M XXX XXX XXX
Net Margin 14% 13% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Grape King Bio Stock Performance

As of April 15, 2025, Grape King Bio's stock price is TWD 133 (or $4).

Grape King Bio has current market cap of TWD 19.6B (or $593M), and EV of TWD 15.4B (or $464M).

See Grape King Bio trading valuation data

Grape King Bio Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$464M $593M XXX XXX XXX XXX $0.37

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Grape King Bio Valuation Multiples

As of April 15, 2025, Grape King Bio has market cap of $593M and EV of $464M.

Grape King Bio's trades at 1.4x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Grape King Bio's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Grape King Bio and 10K+ public comps

Grape King Bio Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $464M XXX XXX XXX
EV/Revenue 1.4x XXX XXX XXX
EV/EBITDA 4.8x XXX XXX XXX
P/E 13.6x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 12.5x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Grape King Bio Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Grape King Bio Valuation Multiples

Grape King Bio's NTM/LTM revenue growth is 5%

Grape King Bio's revenue per employee for the last fiscal year averaged $0.6M, while opex per employee averaged $0.3M for the same period.

Over next 12 months, Grape King Bio's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Grape King Bio's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Grape King Bio and other 10K+ public comps

Grape King Bio Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 5% XXX XXX XXX XXX
EBITDA Margin 29% XXX XXX XXX XXX
EBITDA Growth 2% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 33% XXX XXX XXX XXX
Revenue per Employee $0.6M XXX XXX XXX XXX
Opex per Employee $0.3M XXX XXX XXX XXX
S&M Expenses to Revenue 46% XXX XXX XXX XXX
G&A Expenses to Revenue 7% XXX XXX XXX XXX
R&D Expenses to Revenue 3% XXX XXX XXX XXX
Opex to Revenue 55% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Grape King Bio Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Nutraceuticals & Cosmeceuticals comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Grape King Bio M&A and Investment Activity

Grape King Bio acquired  XXX companies to date.

Last acquisition by Grape King Bio was  XXXXXXXX, XXXXX XXXXX XXXXXX . Grape King Bio acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Grape King Bio

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Grape King Bio

When was Grape King Bio founded? Grape King Bio was founded in 1969.
Where is Grape King Bio headquartered? Grape King Bio is headquartered in Taiwan.
How many employees does Grape King Bio have? As of today, Grape King Bio has 565 employees.
Is Grape King Bio publicy listed? Yes, Grape King Bio is a public company listed on TAI.
What is the stock symbol of Grape King Bio? Grape King Bio trades under 1707 ticker.
When did Grape King Bio go public? Grape King Bio went public in 1982.
Who are competitors of Grape King Bio? Similar companies to Grape King Bio include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Grape King Bio? Grape King Bio's current market cap is $593M
What is the current revenue of Grape King Bio? Grape King Bio's last 12-month revenue is $343M.
What is the current EV/Revenue multiple of Grape King Bio? Current revenue multiple of Grape King Bio is 1.4x.
What is the current revenue growth of Grape King Bio? Grape King Bio revenue growth between 2023 and 2024 was 5%.
Is Grape King Bio profitable? Yes, Grape King Bio is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.